Clinical Trial Update: Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CGF166 for safety, tolerability, and efficacy in adults with unilateral or bilateral severe-to-profound hearing loss has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss
• To Profound Hearing Loss

Drugs mentioned

• CGF166

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-03-30